Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04335513
Other study ID # 19-1767
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date April 30, 2020
Est. completion date July 31, 2023

Study information

Verified date May 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This protocol is an intervention study to determine the best education and monitoring strategy for children ages 2-20 years with pre-symptomatic type 1 diabetes (T1D) because there currently exists no clinical guidelines for management of these children in early-stage T1D. This study hypothesizes that the trajectory of T1D can be changed, substantially reducing HbA1c and risk of DKA at diagnosis, through (1) careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, (2) staged education targeted to assist families in recognizing evolving dysglycemia, and (3) addressing glycemic abnormalities with early initiation of insulin.


Description:

Specific Aims: Perform randomized controlled trial of intensive follow-up of stage 2 T1D participants utilizing continuous glucose monitoring (CGM) technology and early education of families to guide early insulin therapy with the goals of: maintaining HbA1c less than 7.0%. avoiding adverse outcomes: ER visits, hospitalizations, DKA and severe hypoglycemia improving diabetes knowledge through optimal planned education as opposed to 'a crash course' at unexpected diagnosis event. evaluating patient/caregiver satisfaction with diabetes care received evaluating impact of activity on glycemic profile Collect longitudinal biomarkers of beta-cell stress and dysfunction in stage 2 T1D. Use longitudinal CGM data combined with "gold-standard" OGTT and HbA1c measures to provide evidence for CGM-based diagnostic criteria for stage 2 and stage 3 T1D. Perform cost-analysis of intensive follow up protocol.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 84
Est. completion date July 31, 2023
Est. primary completion date July 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years to 20 Years
Eligibility 1. Individuals identified in stage 2 T1D through ongoing screening studies at the Barbara Davis Center (ASK, DAISY, TrialNet, and TEDDY) who have given permission to be contacted about study opportunities. 2. Presence of islet autoimmunity with high risk of progression: i. positive for multiple islet autoantibodies at 2 or more visits -OR- ii. positive for a single high-affinity islet autoantibody at 2 or more visits 3. Evidence of dysglycemia (Stage 2 T1D) using any one of the following criteria: I. Americal Diabetes Association (ADA) criteria: 1. fasting plasma glucose 100-125 mg/dL 2. OR 2-hour OGTT plasma glucose of 140-199 mg/dL 3. OR A1c 5.7-6.4% 4. OR =10% increase in A1c from previous visit II. Dysglycemia on OGTT (TrialNet Criteria): a. glucose above 200 mg/dL on 30, 60 OR 90 minute values III. Dysglycemia on CGM worn for at least 5 days: 1. =15% of values above 140 mg/dL 2. OR peaks = 200 mg/dL on =2 days 3. OR average sensor glucose =120 mg/dL IV. Dysglycemia on finger stick blood glucose: 1. Fasting BG above 110 mg/dL on 2 or more days 2. OR 2 hour post-meal BG above 150 mg/dL on = 2 days 3. OR single random BG > 200 mg/dL

Study Design


Intervention

Other:
Early CGM-guided education and initiation of insulin therapy.
Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.
Usual care: glucometer surveillance and basic education.
Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK. Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes.

Locations

Country Name City State
United States Barbara Davis Center Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver The Leona M. and Harry B. Helmsley Charitable Trust

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Activity Monitoring daily steps Activity tracker average of steps per day from at least 5 days of data at each time point. Average daily steps will be analyzed using linear mixed models incorporating data from all seven time points, with an interaction between group and time to test for differences in change in outcome over time. Contrast statements will be used to test for comparisons of interest (intervention vs controls). Monthly for months 0, 1, 2, 3, 4, 5, and 6 of study
Other Parental anxiety regarding diabetes risk Items from a questionnaire to study the psychological impact of diabetes risk. A 6-item short form of the state portion of the State-Trait Anxiety Inventory (STAI) will be used to assess parent anxiety about the child's diabetes risk at a single point in time. For example, parents were asked how often they feel "worried" specifically when they think about their child's risk of developing diabetes. Responses were scored on a 4-point scale and the 6-item score was then converted to a total score comparable to the 20-item State Anxiety Inventory score. Parents with STAI scores > 40 were considered to be highly anxious. STAI scores will be analyzed using linear mixed models incorporating data from all three time points, with an interaction between group and time to test for differences in change in outcome over time. Contrast statements will be used to test for comparisons of intervention vs controls. Baseline, 6 and 12 months
Other Parental depression symptoms. Items from a questionnaire to study the psychological impact of diabetes risk. A 6-item set of questions quering frequency of depressive symptoms will be used to assess parent depressive symptoms at a single point in time. For example, parents will be asked about frequency of crying spells on a 4 point scale from (1) Not at all to (4) All of the time. Responses are scored from 6 to 24, with higher score indicating increased depressive symptoms. Baseline, 6 and 12 months
Other Parental perception of ability to impact diabetes risk. Items from a questionnaire to study the psychological impact of diabetes risk. A 3 item survey, each item answered on a likert scale from 1-5: (1) strongly agree to (5) strongly disagree. Risk modification belief scoring is scored on 3-15 points with higher score indicating perception that risk of diabetes can be modified. Risk modification scores will be analyzed using linear mixed models incorporating data from all three time points, with an interaction between group and time to test for differences in change in outcome over time. Contrast statements will be used to test for comparisons of intervention vs control Baseline, 6 and 12 months
Other Accuracy of parental risk perception. Items from a questionnaire to study the psychological impact of diabetes risk. The accuracy of parental perception of the child's risk for developing type 1 diabetes (T1D) is scored as accurate or inaccurate on a questionnaire (accurate: indicating the child's T1D risk was higher or much higher than other children's T1D risk; inaccurate: indicating the child's T1D risk was the same, somewhat lower or much lower than other children's T1D risk). Baseline, 6 and 12 months
Other Parental worry regarding diabetes risk. Item from a questionnaire to study the psychological impact of diabetes risk. The frequency of worry regarding whether the child will develop diabetes is scored on a five item scale from (1) Never to (5) Very often. A score of 5 indicates increased level of worry. Baseline, 6 and 12 months
Other Change in height over time Change in z-score of height, using CDC (Centers for Disease Control) standards for gender and age. Baseline and 3, 6, 9 and 12 months
Other Change in weight over time Change in z-score of weight, using CDC standards for gender and age. Baseline and 3, 6, 9 and 12 months
Other Change in BMI over time Change in z-score of BMI using CDC standards for gender and age. Baseline and 3, 6, 9 and 12 months
Other Change in body fat over time Change in body fat percentile using Tanita bioelectrical impedance scale Baseline and 3, 6, 9 and 12 months
Other Presence of one or more islet cell autoantibodies:over time islet autoantibodies measured in the blood: GAD65 autoantibody (GADA), islet antigen 2 autoantibody (IA-2A), insulin autoantibody (IAA), and zinc transporter 8 autoantibody (ZnT8A) Baseline and 3, 6, 9 and 12 months
Other Change in glucose tolerance over time by Oral Glucose Tolerance Test (OGTT) Abnormal glucose tolerance is defined as:
Fasting plasma glucose = 110 mg/dL (6.1 mmol/L) and < 126 mg/dL (7 mmol/L), or 2 hour plasma glucose = 140 mg/dL (7.8 mmol/L) and < 200 (11.1 mmol/L), or 30, 60, 90 minute plasma glucose during OGTT = 200 mg/dL (11.1 mmol/L)
OGTT values diagnostic of diabetes is defined as:
Fasting plasma glucose >126 mg/dL (7 mmol/L), or 2 hour plasma glucose >200 (11.1 mmol/L),
Baseline, 6 months, 12 months
Other Continuous glucose monitor (CGM) % time <60 mg/dL Data obtained for Dexcom G6 wear with at least 5 days of data. Baseline and 3, 6, 9 and 12 months
Other areal bone mineral density of the spine measured by osteodensitometry (DXA) Measured in g/cm2 by Dual-energy X-ray absorptiometry (DXA) 3 and 9 month visits
Other areal bone mineral density of the proximal femur measured by osteodensitometry (DXA) Measured in g/cm2 by Dual-energy X-ray absorptiometry (DXA) 3 and 9 month visits
Other Change in glycemic control over time 1,5 anhydroglucitol Baseline and 3, 6, 9 and 12 months
Other Insulin requirements total, basal and bolus insulin dose (Units/kg/day), both arms Baseline and 3, 6, 9 and 12 months
Other Severe hypoglycemic episodes frequency of severe hypoglycemic episodes (BG < 54 mg/dL) 12 months
Other diabetic ketoacidosis (DKA) episodes frequency of DKA 12 months
Other ER visits and hospitalizations related to glycemia frequency of ER/Hospitalizations 12 months
Other Adverse events number, nature and severity of other adverse events 12 months
Other Assessment of frequency of use of CGM (continuous glucose monitor) system Number of days using CGM 12 months
Other Change in Diabetes Knowledge from 6 month to 12 months follow-up. 35-item diabetes questionnaire with possible responses true/false/don't know. Total score is the number of correct answers out of 35, with more correct answers indicating higher knowledge. Durability of knowledge from 6-month follow-up to 12 month follow-up will be compared between groups 6 months to 12 months follow-up
Primary Change in Diabetes Knowledge from baseline to 6 month follow-up. 35-item diabetes questionnaire with possible responses true/false/don't know. Total score is the number of correct answers out of 35, with more correct answers indicating higher knowledge. Change from baseline to 6-month follow-up will be compared between groups Baseline, 6 months
Primary Continuous glucose monitor (CGM) % time >140 mg/dL Data obtained for Dexcom G6 wear with at least 5 days of data at each time point. Continuous glucose monitor (CGM) % time >140 mg/dL will be analyzed using linear mixed models incorporating data from all 5 time points, with an interaction between group and time to test for differences in change in outcome over time. Contrast statements will be used to test for comparisons of intervention vs controls. Baseline and 3, 6, 9 and 12 months
Secondary Change in HbA1c HbA1c from baseline to 52 weeks, adjusted for baseline Baseline and 3, 6, 9 and 12 months
Secondary % with HbA1c <7.0% Percentage of individuals in each group with HbA1c <7.0% Baseline and 3, 6, 9 and 12 months
Secondary Continuous glucose monitor (CGM) % time in range 60-140 mg/dL Data obtained for Dexcom G6 wear with at least 5 days of data. Baseline and 3, 6, 9 and 12 months
Secondary Continuous glucose monitor (CGM) mean sensor glucose level (mg/dL) Data obtained for Dexcom G6 wear with at least 5 days of data. Baseline and 3, 6, 9 and 12 months
Secondary Continuous glucose monitor (CGM) standard deviation sensor glucose level (mg/dL) Data obtained for Dexcom G6 wear with at least 5 days of data. Baseline and 3, 6, 9 and 12 months
Secondary Continuous glucose monitor (CGM) coefficient of variation sensor glucose level (mg/dL) Data obtained for Dexcom G6 wear with at least 5 days of data. Baseline and 3, 6, 9 and 12 months
Secondary Change in Pediatric Quality of Life Inventory (PedsQL 4.0) score over time The PedsQL 4.0 measures health-related quality of life across the domains of Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning.
ThePedsQL has parallel forms for parents of children aged 2-4, 5-7, 8-12, and 13-18 years. The child version has parallel forms for children aged 5-7, 8-12, and 13-18. Responses to items use a 5-point Likert scale (0 = never a problem, 4 = almost always a problem). Items are reverse scored and transformed to a 0 to 100 scale with higher scores indicating better quality of life.
Baseline and 3, 6, 9 and 12 months
Secondary Change in C-peptide response to Oral Glucose Tolerance Test (OGTT) C-peptide measurement during standard OGTT, Area under the curve (AUC) Baseline, 6 months, 12 months
Secondary Change in insulin response to Oral Glucose Tolerance Test (OGTT) insulin measurement during standard OGTT, Area under the curve (AUC) Baseline, 6 months, 12 months
Secondary Diabetes attitude survey change over time 10 item survey, each item answered on a likert scale from 1-5: (1) strongly disagree to (5) strongly agree. Scoring is on 4 scales: (1) "Value of Tight Control", scored on 4-20 points with higher score indicating agreement with importance of control; (2) "Psychosocial Impact", scored on 2-10 points with higher score indicating agreement with high impact of diabetes on psychosocial factors; (3) "Patient Autonomy", scored on 2-10 points with higher score indicating agreement with value of autonomy; and (4) "Confidence", scored on 2-10 points with higher score indicating confidence in knowledge and skills. Baseline, 6 months, 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany